Hutchinson Institute for Cancer Outcomes Research

Research Priorities

Dr. Gary Lyman, co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR), is partnering with care providers, insurance companies, patient advocates, drug companies and other researchers to untangle the financial burden cancer patients face through treatment.

HICOR is developing and testing new methods to use value of information 

The number of cancer patients is expected to increase by more than 20 percent between 2010 and 2020.  This increase in cancer incidence and the decline of public and private funding will create a tremendous burden and makes it imperative that research is prioritized by those having the greatest impact.  The challenge is finding ways to prioritize research.

HICOR investigators are developing and testing new methods to use value of information – a systematic, quantitative approach to evaluate the societal value of a clinical trial – to help prioritize research with the most expected value to society.   

The Southwest Oncology Group (SWOG), a large United States cancer clinical trials cooperative group, is testing these methods.  The best methods will aid decision makers in evaluating future research and prioritizing studies that will have the most impact.

HICOR investigator, Lotte Steuten and colleagues have proposed a framework for evaluation of the technology development pathway.  Her early-cycle economic evaluation will use analytic approach technologies that have the potential to increase the return on investment. 

Fred Hutch public health researchers, Joshua Roth and Garnet Anderson, led research showing that the Women's Health Initiative, one of the largest National Institutes of Health-funded studies ever conducted on women, provided a net economic return of $37.1 billion, providing a return of approximately $140 on every dollar invested in the trial.

Research Focus

  • Financial impact of cancer
  • Cancer outcomes
  • Cost-effectiveness alongside clinical trials
  • Comparative effectiveness research
  • Economic assessment of technologies and treatments
  • Cancer policy
  • Value of information
  • Cancer-care delivery research